LOGIN  |  REGISTER

Latest Psychedelic Stock News

Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference

July 12
Last Trade: 1.70 0.09 5.59

Vancouver, Canada, July 12, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces its participation in the upcoming Psychedelic Medicine – Israel 2024 conference. This event will take place in Tel Aviv, Israel from July...Read more


Algernon Pharmaceuticals Announces Private Placement

July 11
Last Trade: 0.13 0.02 13.04

VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces a non-brokered private placement for gross proceeds of $250,000 (the “Offering”) of units (the “Units”) at an issue price of $0.12 per Unit. Each Unit will consist of one Class A common share in the...Read more


Numinus Wellness Announces Third Quarter Fiscal 2024 Results

July 11
Last Trade: 0.05 0.00 0.00

Q3 Fiscal 2024 Highlights Revenue of $4.3 million, a 1.9% decline over Q2 2024 Gross profit of $1.0 million, a 9.8% decline over Q2 2024 Cash position of $3.7 million as of May 31, 2024 Transitioned out of Canadian clinical operations through an agreement with the Canadian Centre for Psychedelic Healing ("Field Trip Health") Enrolment in Numinus training programs increased to over 1,650 learners, compared to over 1,400 in Q2 2024,...Read more


Enveric Biosciences Announces Patent Granted for Drug Candidate

July 10
Last Trade: 0.52 0.0096 1.89

US patent includes broad claims for treating brain neurological disorders CAMBRIDGE, Mass. / Jul 10, 2024 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, today announces the expansion of protection for potential clinical indications for its EB-002 drug candidate through the...Read more


Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety Disorders

July 8
Last Trade: 1.01 0.03 3.06

Extensive Issued and Pending IP Patent Applications Acquired with License Agreement SARASOTA, FL, July 08, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into an exclusive, global license...Read more


NRx Pharmaceuticals to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for Filing

June 28
Last Trade: 2.48 0.06 2.48

New Drug Application (NDA) for Accelerated Approval planned for NRX-101 in people with bipolar depression and akathisia in 2024, based on two positive trials 1 2 and Breakthrough Therapy Designation. Potential revenue in 2025 NDA for NRX-100 (IV ketamine) in suicidal depression in advanced preparation for submission in 2024; based on four positive trials 3 4 5 6 and Fast Track Designation. Potential revenue in 2025 Gaining these...Read more


Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment

June 28
Last Trade: 1.70 0.09 5.59

Vancouver, Canada, June 28, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces advancement in its proprietary MEAI- based binge behavior regulator program through the granting of patent approval in Hong Kong by the...Read more


Optimi Health and Mind Medicine Australia Launch OptiMed Prescriber Portal for Australian Psychiatrists

June 27
Last Trade: 0.31 -0.05 -12.86

Vancouver, British Columbia--(Newsfile Corp. - June 27, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-approved, GMP-compliant pharmaceutical drug manufacturer specializing in the controlled substances MDMA and botanical psilocybin, is pleased to announce the launch of OptiMed, an online prescriber portal designed to provide Australian psychiatrists with comprehensive...Read more


FSD Pharma Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in Australia

June 27
Last Trade: 0.14 -0.003 -2.05

TORONTO, ON / ACCESSWIRE / June 27, 2024 / FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that it has received approval by the human ethics review committee (HREC) in Australia for its trial entitled "A Phase 1, Randomized, Double-Blind,...Read more


Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety

June 26
Last Trade: 1.01 0.03 3.06

Amplify Bio to complete GLP study of SPC-15 Novel Intranasal Therapeutic Silo study advances SPC-15 towards first-in-human trial SARASOTA, FL, June 26, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has...Read more


BetterLife Pharma To Present BETR-001 Preclinical Data at the 2024 Conference of the Federation of European Neuroscience Societies (FENS) in Vienna, Austria

June 26
Last Trade: 0.16 0.00 0.00

VANCOUVER, British Columbia, June 26, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that its scientific collaborators, Drs. Vern Lewis and Argel Aguilar-Valles from Carleton University’s Department of Neuroscience...Read more


Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights

June 26
Last Trade: 0.32 0.03 10.42

Received U.S. Food and Drug Administration (“FDA”) Breakthrough Therapy Designation (“BTD”) for CYB003, its proprietary deuterated psilocybin analog in development for the adjunctive treatment of Major Depressive Disorder (“MDD”) Clinical site selection complete for Phase 3 multinational study of CYB003, which is expected to begin in summer 2024 Cash totaled C$209 million as of March 31, 2024 Initiated a Phase 2 study of CYB004, its...Read more


Compass Pathways appoints Lori Englebert as Chief Commercial Officer

June 26
Last Trade: 6.97 -0.25 -3.46

New executive appointment made ahead of pivotal study results, potential regulatory approval and subsequent commercialization of investigational COMP360 psilocybin treatment Latest of several key executive team hires, rounding out team to take Compass through phase 3 and beyond LONDON, June 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to...Read more


Health Canada Issues Three Export Permits to Optimi Health to Supply Patients Under Australia's Authorised Prescriber Scheme

June 25
Last Trade: 0.31 -0.05 -12.86

The Company will ship 160 doses of MDMA and psilocybin to Australian psychiatrists for the treatment of patients with PTSD and Treatment-Resistant Depression. Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-approved, GMP-compliant pharmaceutical drug manufacturer specializing in the controlled substances MDMA and...Read more


Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate

June 25
Last Trade: 0.52 0.0096 1.89

EB-003 is a novel, neuroplastogenic molecule designed to treat severe mental health disorders without the hallucinogenic effect typically associated with psychedelic-based compounds Enveric is advancing pre-clinical development of EB-003 with a pre-IND meeting targeted for early 2025 CAMBRIDGE, Mass. / Jun 25, 2024 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to...Read more


MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing

June 24
Last Trade: 0.59 -0.01 -1.82

New preclinical studies suggest that, unlike traditional ketamine, MIRA's oral ketamine analog Ketamir-2 does not induce hyper-locomotor activity, indicative of psychotic symptoms, offering the potential for safer mental health treatments MIAMI, June 24, 2024 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a leading pre-clinical-stage pharmaceutical company focused on the treatment of neurologic...Read more


Mind Medicine to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

June 21
Last Trade: 7.46 -0.01 -0.13

NEW YORK / Jun 21, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference being held on June 27, 2024. A webcast of the fireside chat will be...Read more


Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment

June 20
Last Trade: 1.70 0.09 5.59

Vancouver, Canada, June 20, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, recently announced that it signed an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of...Read more


Mind Medicine Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)

June 20
Last Trade: 7.46 -0.01 -0.13

Aligned on requirements for Phase 3 clinical development of MM120 for the treatment of GAD Initiation of Phase 3 program remains on schedule to begin in second half of 2024 NEW YORK / Jun 20, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the completion of the...Read more


Numinus Wellness Announces Strategic Acquisition of MedBright AI

June 20
Last Trade: 0.05 0.00 0.00

Plans name change to "Numinus Intelligence" leveraging its current revenue-generating operations to AI-enable mental health clinics across the U.S. The strategic combination merges MedBright's AI-enabled clinical solution capabilities with Numinus' deep data and vast experience with drug-assisted mental health treatment to improve clinical operations and capitalize on reimbursable offerings Leaders from MedBright AI team with...Read more


MindBio Therapeutics Reports Sustained Antidepressant Response from MB22001 in Depression Clinical Trials

June 20
Last Trade: 0.03 -0.01 -25.00

Rapid, robust, and clinically significant reduction in depression symptoms Trials of MB22001 show substantial improvements in mood, energy, creativity, wellbeing, depression and sleep, including REM sleep. One month post cessation of treatment, the antidepressant response is sustained with a 65% overall reduction in depressive symptoms. VANCOUVER, BC / ACCESSWIRE / June 20, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)...Read more


Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry

June 18
Last Trade: 4.06 -0.30 -6.88

CORAL GABLES, Fla., June 18, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the publication of REL-1017 clinical data from the Reliance I Study in the peer-reviewed journal, The Journal of Clinical Psychiatry.  The article is titled, "Efficacy and Safety of Esmethadone (REL-1017) in Patients with Major...Read more


NRx Pharmaceuticals Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors

June 18
Last Trade: 2.48 0.06 2.48

Dr. Dennis McBride brings extensive experience in Neuroscience and its interface with Information and Medical Technology Retired at a rank that is the civilian equivalent of a senior flag officer from the United States Navy RADNOR, Pa., June 18, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that the Company has...Read more


BetterLife Pharma Announces Closing of Private Placement

June 14
Last Trade: 0.16 0.00 0.00

VANCOUVER, British Columbia, June 14, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that it has closed a non-brokered private placement, previously announced on May 3, 2024, pursuant to which the Company issued...Read more


FSD Pharma Enters Into an Exclusive Option Agreement With the University of Southern California To Evaluate Novel Dietary Supplement Technology for unbuzzd(TM) and Other Business Applications

June 13
Last Trade: 0.14 -0.003 -2.05

TORONTO, ON / ACCESSWIRE / June 13, 2024 / FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that it entered into an exclusive option agreement with the University of Southern California (USC) to evaluate dietary supplement technology for...Read more


MindBio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial

June 12
Last Trade: 0.03 -0.01 -25.00

VANCOUVER, BC / ACCESSWIRE / June 12, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), a leading biopharmaceutical company in psychiatric medicine development using microdoses of psychedelic medicines, is delighted to report positive secondary data from its world-first take-home microdosing depression trial using MB22001 completed earlier this year. Data from MindBio's Phase 2A Depression trial...Read more


Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia

June 7
Last Trade: 1.01 0.03 3.06

Analytical testing has confirmed optimal formulation for upcoming studies SARASOTA, FL, June 07, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced a successful series of development activities for the Company’s SP-26...Read more


Numinus Wellness Comments on FDA Advisory Committee Meeting for Investigational MDMA-Assisted Therapy for PTSD

June 7
Last Trade: 0.05 0.00 0.00

VANCOUVER, BC, June 7, 2024 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a leader in mental health care specializing in innovative and evidence-based treatments, comments on the results of June 4, 2024 meeting of the U.S. Food and Drug Administration's ("FDA") Psychopharmacologic Drugs Advisory Committee ("PDAC"). The independent committee reviewed Lykos Therapeutics' new drug application for...Read more


Universal Ibogaine Announces Closing of Private Placement Financing

June 7
Last Trade: 0.01 0.00 0.00

Calgary, AB – TheNewswire - June 7, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises that it has closed its previously announced (see News Release of April 12) non-brokered private placement offering of common shares (the “Offering”) and has issued a total of 13,500,000 common shares at a price of $0.02 per...Read more


Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

June 6
Last Trade: 1.01 0.03 3.06

SARASOTA, FL, June 06, 2024 (GLOBE NEWSWIRE) -- SARASOTA, FL, June 6, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced the closing of its previously announced registered direct offering priced at-the-market under...Read more


Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

June 5
Last Trade: 1.01 0.03 3.06

SARASOTA, FL, June 05, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into definitive agreements for the purchase and sale of 917,432 shares of common stock (or common stock equivalents in lieu...Read more


Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety

June 4
Last Trade: 1.01 0.03 3.06

Clinical roadmap unveiled for novel and proprietary intranasal PTSD treatment SARASOTA, FL, June 04, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced its submission of a pre-Investigational New Drug (pre-IND)...Read more


FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication

June 4
Last Trade: 0.14 -0.003 -2.05

TORONTO, ON / ACCESSWIRE / June 4, 2024 / FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today confirms that it has received institutional review board (IRB) approval for its METAL-2 trial in the USA. This IRB approval allows our team to begin recruiting clinical...Read more


Optimi Health Awarded Drug Establishment Licence From Health Canada

June 3
Last Trade: 0.31 -0.05 -12.86

VANCOUVER, BC, June 3, 2024 /CNW/ - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a leading Health Canada-licensed psychedelics pharmaceutical manufacturer specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to announce that it has been awarded a Drug Establishment Licence (DEL) from Health Canada for the manufacturing and sale of its MDMA and psilocybin...Read more


Filament Health Announces Authorization Of Phase 2 Clinical Trial For PEX010 In The Treatment Of Methamphetamine Use Disorder

June 3
Last Trade: 0.05 0.005 11.11

Company study investigating PEX010, Filament's botanical psilocybin drug candidate, has been authorized by both FDA and Health Canada VANCOUVER, BC, June 3, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE:7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced Health Canada and the United States Food and Drug Administration ("FDA") authorization for a...Read more


Filament Health Announces Warrant Exercise And Note Conversion By Negev Capital And Concurrent Private Placement Of Common Shares To Benjamin Lightburn, Chief Executive Officer

June 3
Last Trade: 0.05 0.005 11.11

VANCOUVER, BC, June 3, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that it has entered into agreements with Negev Capital Fund One, LP ("Negev"), a leading psychedelic drug development venture fund and existing investor in the Company, and Benjamin Lightburn, the Chief Executive Officer and...Read more


Optimi Health Announces Closing of Fully Subscribed $1,500,000 Financing

May 31
Last Trade: 0.31 -0.05 -12.86

VANCOUVER, BC, May 31, 2024 /CNW/ - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada-licensed GMP psychedelics pharmaceutical manufacturer specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to announce it has closed a third and final tranche of its non-brokered private placement (the "Offering"). The Offering consisted of units (each a "Unit") at CAD$0.30 per...Read more


Numinus Wellness and Cybin Embark on a Groundbreaking Journey: Pioneering Phase 3 Trials for Major Depressive Disorder

May 30
Last Trade: 0.05 0.00 0.00

Vancouver, British Columbia--(Newsfile Corp. - May 30, 2024) - In a significant stride towards transforming mental health care, Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) (FSE: LR23) has proudly announced that its research site, Cedar Clinical Research (CCR), has been selected for Cybin's Phase 3 pivotal multinational clinical trial of CYB003. Aimed at revolutionizing the treatment of Major Depressive Disorder (MDD), this...Read more


Incannex Healthcare: Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

May 30
Last Trade: 2.75 -0.0094 -0.34

NEW YORK and MELBOURNE, Australia, May 30, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies is pleased to announce that patient dosing has commenced in the Company’s Phase 2/3 clinical trial to assess safety and efficacy of IHL-42X in patients with obstructive sleep...Read more


Numinus Wellness Receives Health Canada Approval for Study into Group Model for MDMA-Assisted Therapy

May 30
Last Trade: 0.05 0.00 0.00

VANCOUVER, BC, May 30, 2024 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, announces that Health Canada has approved the Company's Clinical Trial Application to examine the feasibility of a group model in MDMA-assisted psychotherapy...Read more


Optimi Health Secures Import Permit from Mind Medicine Australia for MDMA and Psilocybin Capsules

May 29
Last Trade: 0.31 -0.05 -12.86

VANCOUVER, British Columbia, May 29, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed GMP psychedelics pharmaceutical manufacturer, specializing in controlled substances such as psilocybin and MDMA, is pleased to announce that it has received an import permit from Mind Medicine Australia (MMA) to export its GMP MDMA and psilocybin capsules to supply approved...Read more


NRx Pharmaceuticals Presents Landmark Trial of NRX-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: NRX-101 is the First Oral Antidepressant Demonstrated to Reduce Suicidality

Poster presentation of "A Randomized, Double-Blind Controlled Comparison of NRX-101 (D-cycloserine/lurasidone) to Lurasidone for Adults with Bipolar Depression and Subacute Suicidal Ideation or Behavior" NRX-101 demonstrated a similar antidepressant effect (MADRS reduction ~50%) compared to lurasidone, the Standard of Care drug NRX-101 demonstrated a 58% relative reduction in time to sustained remission from suicidality (P=.05)...Read more


FSD Pharma Submits a Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication

May 28
Last Trade: 0.14 -0.003 -2.05

TORONTO, ON / ACCESSWIRE / May 28, 2024 / FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today confirms the submission of a clinical trial protocol to assess the safety and efficacy of Unbuzzd™ in healthy volunteers (METAL-2 trial). The clinical trial protocol was...Read more


Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder

May 22
Last Trade: 0.31 -0.05 -12.86

VANCOUVER, British Columbia, May 22, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA, has entered a Letter of Intent (LOI) with ATMA Journey Centers (ATMA). ATMA is a pioneering Canadian firm focused on advancing innovative solutions in...Read more


Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention

May 21
Last Trade: 1.01 0.03 3.06

The study has identified a potentially new drug formulation that could potentially extend the period of remission and prevent relapse in patients with depression. SARASOTA, FL, May 21, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic...Read more


FSD Pharma Provides Update on Celly Nu's New Packaging for unbuzzd(TM)

May 16
Last Trade: 0.14 -0.003 -2.05

TORONTO, ON / ACCESSWIRE / May 16, 2024 / FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRA:0K9A) ("FSD Pharma"), provides an update by way of a news release issued by Celly Nutrition Corp. ("Celly Nu"), its new packaging and logo of unbuzzd™ expected to launch this summer, an innovative beverage product that is scientifically formulated from a proprietary blend of vitamins, minerals and botanical extracts designed to support the body's...Read more


PharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine

May 15
Last Trade: 0.23 0.005 2.27

TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo Therapeutics Inc. (“Sairiyo”), a company that is forty-nine percent (49%) owned by PharmaTher and fifty-one percent (51%) owned by PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug"), has submitted to the Australian Human Research Ethics...Read more


Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results

May 15
Last Trade: 0.52 0.0096 1.89

Revealed seven classes of promising novel drug candidates discovered using Enveric’s Psybrary™ and PsyAI™ drug discovery and artificial intelligence (AI) platforms Launched business development campaign that resulted in the execution of seven non-binding term sheets with four strategic partners that upon entering into definitive agreements and performing pursuant to the terms thereof could potentially total up to approximately $410...Read more


Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders

May 14
Last Trade: 0.52 0.0096 1.89

MindBio to develop the novel psilocin prodrug for neuropsychiatric indications utilizing microdosing to reduce or eliminate hallucinogenic impact of psychedelic compounds CAMBRIDGE, Mass. / May 14, 2024 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and...Read more


BetterLife Pharma Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001

May 14
Last Trade: 0.16 0.00 0.00

VANCOUVER, British Columbia, May 14, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), announced it has completed its animal GLP cardiopulmonary safety study of BETR-001. The study demonstrated that oral BETR-001 at doses over...Read more


NRx Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

May 14
Last Trade: 2.48 0.06 2.48

2024 Catalysts: Positive Clinical Data, Two Planned NDAs, Company Launch of Hope Therapeutics; FDA QIDP award in cUTI and New Schizophrenia Opportunity Executed Term Sheet from an institutional investor for an initial $7.5 million note, subject to common closing requirements, primarily to replace current debt, clearing the path to a Hope Therapeutics share distribution, with provision for funding up to $30 million to fund pipeline...Read more


Filament Health Announces First Quarter 2024 Financial Results And Operational Highlights

May 14
Last Trade: 0.05 0.005 11.11

VANCOUVER, BC, May 14, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its first quarter financial results and operational highlights for the period ended March 31, 2024. "This quarter we have continued to advance Filament's drug development efforts in substance use disorders, as evidenced by the opening...Read more


Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product

May 10
Last Trade: 1.70 0.09 5.59

The global market of no- and low-alcohol beverages estimated at over $13 billion in 2023 Vancouver, Canada, May 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces advancement in its proprietary MEAI- based...Read more


PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine

May 10
Last Trade: 0.23 0.005 2.27

TORONTO, May 10, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced receipt of an Amendment Acknowledgment Letter (“AAL”) for its Priority Original Abbreviated New Drug Application (“ANDA”) for Ketamine from the U.S. Food and Drug Administration (the “FDA”) and assigned a Generic Drug User Fee Amendments of 2022 (“GDUFA”) goal...Read more


MindMed Reports First Quarter 2024 Financial Results and Business Updates

May 8
Last Trade: 7.46 -0.01 -0.13

Announced positive Phase 2b clinical trial results for MM120 in Generalized Anxiety Disorder (GAD), demonstrating clinically and statistically significant activity through 12 weeks after treatment The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to MM120 for the treatment of GAD in adults Cash and cash equivalents of $252.3 million as of March 31, 2024 Company to host a conference call today at 4:30...Read more


Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights

May 8
Last Trade: 6.97 -0.25 -3.46

COMP360 phase 3 pivotal program in treatment-resistant depression (TRD) on track for top-line COMP005 trial data in fourth quarter 2024, COMP006 trial top-line data expected mid-2025 Compass announces positive phase 2 COMP360 data in post-traumatic stress disorder (PTSD) Michael Gold to join Compass as Head of R&D Compass enters into additional commercial collaborations, including with Reliant Medical Group, part of Optum Care...Read more


Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

May 8
Last Trade: 6.97 -0.25 -3.46

Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed Early and clinically meaningful improvement from baseline in mean CAPS-5 total score (29.5 point reduction at week 12), with change from baseline in mean SDS total score (14.4 point reduction at week 12) 81.8% response (reduction of ≥ 15 points in CAPS-5 score), 63.6% remission (total CAPS-5 ≤ 20) rates at week 4 with 77.3%...Read more


Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 8
Last Trade: 4.06 -0.30 -6.88

CORAL GABLES, Fla., May 8, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the first quarter ended March 31, 2024. The Company will host a conference call today, Wednesday, May 8, at 4:30 PM Eastern Time/1:30 PM Pacific...Read more


FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia

May 7
Last Trade: 0.14 -0.003 -2.05

TORONTO, ON / ACCESSWIRE / May 7, 2024 / FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces the submission to ethics of a trial entitled "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate...Read more


Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment

May 7
Last Trade: 1.70 0.09 5.59

Vancouver, Canada, May 07, 2024 (GLOBE NEWSWIRE) --  Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces the signing of an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of...Read more


NRx Pharmaceuticals Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression

May 6
Last Trade: 2.48 0.06 2.48

Both drugs demonstrated > 50% response for treating depression. NRX-101 demonstrated a mean 76% reduction in symptoms of akathisia compared to lurasidone that was sustained over 42 days (Effect Size .37; P=0.025), using prespecified analytic methodology memorialized in FDA Special Protocol Agreement. Levels of akathisia with NRX-101 were essentially zero at day 42 This safety advantage was previously reported in the Company's...Read more


Mind Medicine Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York

May 4
Last Trade: 7.46 -0.01 -0.13

-A single oral administration of MM120 100 µg met its primary and key secondary endpoints and maintained clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with a 65% clinical response rate and a 48% clinical remission rate- -MindMed also presents two new epidemiology studies quantifying the burden of GAD in the US- -APA Annual Meeting, the largest psychiatric gathering in the world, is the first...Read more


PharmAla Biotech Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy

May 3
Last Trade: 0.11 -0.005 -4.35

TORONTO, May 03, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has officially launched its Prescribers Portal for medical practitioners with prescribing power to learn more about MDMA, its effects,...Read more


GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates

May 3
Last Trade: 11.99 0.09 0.76

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and of 6-month open-label extension phase in Q1 2025 Phase 2a clinical trial of GH001 in postpartum depression on track for expected completion in Q3 2024 Cash, cash equivalents, other financial assets and marketable securities of $214.0 million expected to provide cash runway into...Read more


Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment

May 2
Last Trade: 6.97 -0.25 -3.46

LONDON, May 02, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Mindful Health Solutions (MHS), one of the US’s leading providers of innovative behavioral health care, today announced that they have entered into a research collaboration agreement to inform the development of a scalable and...Read more


MindBio Therapeutics Scientists Present Landmark Women’s Health Trials. Company To Release Phase 2A Depression Trial Secondary Data This Month

May 2
Last Trade: 0.03 -0.01 -25.00

VANCOUVER, BC / ACCESSWIRE / May 2, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), a clinical stage biopharma company pioneering microdosing treatments for mental health conditions showcases Dr Rachael Sumner, presenting MindBio's landmark women's health trials. The trials in women's health aim to address a huge unmet need in...Read more


BetterLife Pharma Advances BETR-001 IND-enabling Studies

May 1
Last Trade: 0.16 0.00 0.00

VANCOUVER, British Columbia, May 01, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of non-hallucinogenic LSD-based therapeutics for mental disorders, announces that it has advanced in its IND-enabling studies for BETR-001, a non-hallucinogenic derivative of LSD (lysergic acid...Read more


PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine

May 1
Last Trade: 0.23 0.005 2.27

TORONTO, May 01, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo Therapeutics Inc. (“Sairiyo”), a company that is forty-nine percent (49%) owned by PharmaTher and fifty-one percent (51%) owned by PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug”), has completed its clinical and regulatory package to evaluate...Read more


FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication

April 30
Last Trade: 0.14 -0.003 -2.05

TORONTO, ON / ACCESSWIRE / April 30, 2024 / FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRA:0K9A) ("FSD Pharma" of the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory, and metabolic disorders, today announced that it entered into agreement with Applied Science and Performance Institute (ASPI) in Tampa,...Read more


NRx Pharmaceuticals Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression

April 30
Last Trade: 2.48 0.06 2.48

NRX-101 is first oral antidepressant to show 33% advantage in sustained remission in suicidality (not statistically significant at this sample size) and 75% advantage in relief from Akathisia relative to lurasidone - never previously shown with an oral antidepressant. Suicidality signal met the study's promising zone criteria and the akathisia signal approached statistical significance (P=0.076)  Both NRX-101...Read more


MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials

April 30
Last Trade: 0.03 -0.01 -25.00

ASSESSING THE EFECTS OF MICRODOSING MB22001 IN MENSTRUATING PERSONS WITH AND WITHOUT PREMENSTRUAL SYNDROME AND PREMENSTRUAL DYSPHORIC DISORDER Multiple clinical trials in women's health approved for take-home use of MB22001 MB22001 aims to address huge unmet need in the ~25% of women experiencing PMS symptoms MB22001 to be used acutely to address the mood sensitive phases of the menstrual cycle World first clinical trials will...Read more


Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression

April 29
Last Trade: 6.97 -0.25 -3.46

LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Journey Clinical, a leading psychedelic-assisted psychotherapy platform with the largest network of licensed therapists focused on psychedelics in the US, today announced they have entered into a research collaboration agreement to...Read more


Universal Ibogaine provides update on planned Clinical Trial Application process

April 29
Last Trade: 0.01 0.00 0.00

Calgary, AB – TheNewswire - April 29, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, is pleased to provide an update on its planned Clinical Trial Application (“CTA”) process.  UI has engaged a new clinical research organization (“CRO”) to complete the process of compiling UI’s submission to Health Canada for...Read more


Mind Medicine to Present at Upcoming May Medical Conferences

April 25
Last Trade: 7.46 -0.01 -0.13

NEW YORK / Apr 25, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder (GAD), as well as multiple presentations describing the epidemiology and growing burden of GAD...Read more


Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024

April 24
Last Trade: 0.13 0.02 13.04

VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro), along with the Centre for Human Drug Research (CHDR), will present its Phase 1 stroke study data at the Interdisciplinary...Read more


Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research

April 23
Last Trade: 0.31 -0.05 -12.86

VANCOUVER, British Columbia, April 23, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, is thrilled to announce an innovative research and development partnership with the Kwantlen Polytechnic University Applied Genomics Centre (KPU-AGC). The project, entitled, “Genetic Identification of Psilocybin Containing Mushroom,” will...Read more


Silo Pharma Announces Positive Results for Intranasal PTSD Treatment

April 23
Last Trade: 1.01 0.03 3.06

Intranasal Delivery of SPC-15 shows rapid and effective drug exposure for PTSD Therapy SARASOTA, FL, April 23, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced positive data in the final validation report from the...Read more


MindBio Therapeutics Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry

April 23
Last Trade: 0.03 -0.01 -25.00

MindBio scientist's sleep research published in prestigious peer reviewed scientific journal MindBio's proprietary treatment protocol using MB22001, results in longer sleep and better quality of sleep the day after microdosing VANCOUVER, BC / ACCESSWIRE / April 23, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), a clinical stage biopharma company uniquely pioneering novel treatments for...Read more


PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine

April 18
Last Trade: 0.23 0.005 2.27

TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced receipt of a Complete Response Letter (“CRL”) for its Priority Original Abbreviated New Drug Application (“ANDA”) for Ketamine that was accepted by the U.S. Food and Drug Administration (the “FDA”) and assigned a Generic Drug User Fee Amendments of 2022...Read more


Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry

April 18
Last Trade: 0.32 0.03 10.42

- Publication explores structure-activity relationships (“SAR”) of a broad range of 2C-X analogs - - Innovative research led to the discovery of CYB210010, a potent and long-acting serotonin 5-HT2 receptor agonist with favorable pharmacokinetic properties - TORONTO / Apr 18, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to...Read more


NRx Pharmaceuticals Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections

April 17
Last Trade: 2.48 0.06 2.48

New data demonstrates no impact of NRX-101 on gut or vaginal flora – considered primary causes of pseudomembranous colitis due to C difficile and vaginal yeast infections NRX-101 previously demonstrated potent activity against resistant urinary pathogens and has been shown to be fully excreted, unmetabolized, in the urine NRX-101 has received FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation in...Read more


Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders

April 17
Last Trade: 1.70 0.09 5.59

Tel Aviv, Israel / Vancouver, Canada, April 17, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced an exclusive licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This...Read more


NRx Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock

April 17
Last Trade: 2.48 0.06 2.48

RADNOR, Pa., April 17, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the Company. The offering is subject to market conditions and there can be no assurance as to whether...Read more


PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine

April 16
Last Trade: 0.23 0.005 2.27

TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, provides an update of its Priority Original Abbreviated New Drug Application (“ANDA”) for Ketamine that was accepted by the U.S. Food and Drug Administration (the “FDA”) and assigned a Generic Drug User Fee Amendments of 2022 (“GDUFA”) goal date of April 29, 2024. As announced...Read more


Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder

April 16
Last Trade: 0.32 0.03 10.42

Newly issued patent expected to provide exclusivity until at least 2041 and includes claims to pharmaceutical compositions within the Company’s proprietary deuterated psilocybin analog program  Cybin’s patent portfolio now includes more than 50 granted patents and over 170 pending applications  Company expects to commence enrollment for a multinational, multisite Phase 3 program evaluating CYB003 in Major Depressive Disorder...Read more


NRx Pharmaceuticals Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)

April 15
Last Trade: 2.48 0.06 2.48

Formulation based on prior patents by NRx founder Achieved pH neutral formulation of ketamine, potentially enabling both intravenous (IV) and subcutaneous (SQ) administration Company expects Composition of Matter patent protection Company previously executed joint development agreement with US manufacturer of insulin pumps RADNOR, Pa., April 15, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals",...Read more


BetterLife Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

April 15
Last Trade: 0.16 0.00 0.00

Vancouver, British Columbia--(Newsfile Corp. - April 15, 2024) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 16 and 17 at the Metro Toronto Convention Centre. Dates: Tuesday April...Read more


Numinus Wellness Announces Second Quarter Fiscal 2024 Results

April 12
Last Trade: 0.05 0.00 0.00

Q2 Fiscal 2024 Highlights Cash position of $6.6 million as of February 29, 2024 Gross profit of $0.5 million, a 22.7% decline over Q1 2024 Revenue of $5.0 million, a 15.4% decline over Q1 2024 Enrolment in Numinus training programs doubled to over 1,400 learners, compared to over 700 in Q1 2024 Managed 15 clinical trials at Cedar Clinical Research Provided 17,661 client appointments in Numinus Wellness Clinics Subsequent to...Read more


Universal Ibogaine Announces New Private Placement Financing

April 12
Last Trade: 0.01 0.00 0.00

Calgary, AB – TheNewswire - April 12, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises that it intends to undertake a non-brokered private placement offering of up to 30,000,000 common shares at a price of $0.02 per share, for proceeds of up to $600,000 (the “Offering”). Completion of the Offering is...Read more


BetterLife Pharma To Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

April 11
Last Trade: 0.16 0.00 0.00

VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that Dr. Ahmad Doroudian, Chief Executive Officer, and Dr. Hooshmand Sheshbaradaran, Chief Operating Officer, will present at the...Read more


Sign Up To Get Daily Life Science Stock News

Please review our Disclaimer and Privacy Policy before subscribing.

Today's Psychedelic Gainers

 
CompanyChangeLast Trade
GH Research 0.09 0.76 $11.99
Clearmind Medicine 0.09 5.59 $1.70
NRx Pharmaceuticals 0.06 2.48 $2.48
Cybin 0.03 10.42 $0.32
Silo Pharma 0.03 3.06 $1.01
Algernon Pharmaceuticals 0.02 13.04 $0.13
Enveric Biosciences 0.0096 1.89 $0.52
Filament Health 0.005 11.11 $0.05
PharmaTher 0.005 2.27 $0.23
Bright Minds Biosciences 0.0024 0.25 $0.96

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

COPYRIGHT ©2023 HEALTH STOCKS HUB